ACADIA Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ACAD, ACADIA Pharmaceuticals Inc, priceseries

ACADIA Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
23.91
Close
24.40
High
24.62
Low
23.88
Previous Close
24.04
Daily Price Gain
0.36
YTD High
27.81
YTD High Date
Feb 16, 2022
YTD Low
20.74
YTD Low Date
Jan 24, 2022
YTD Price Change
0.01
YTD Gain
0.04%
52 Week High
49.23
52 Week High Date
Mar 8, 2021
52 Week Low
15.68
52 Week Low Date
Sep 14, 2021
52 Week Price Change
-21.38
52 Week Gain
-46.70%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 22. 2016
27.67
Jan 11. 2017
30.04
12 Trading Days
8.57%
Link
LONG
Jan 26. 2017
31.37
Feb 28. 2017
38.05
22 Trading Days
21.29%
Link
LONG
Jul 5. 2018
16.64
Jul 9. 2018
17.54
2 Trading Days
5.41%
Link
LONG
Sep 18. 2018
14.28
Oct 10. 2018
20.67
16 Trading Days
44.76%
Link
LONG
Dec 31. 2018
16.17
Jan 22. 2019
20.46
14 Trading Days
26.54%
Link
LONG
Jan 23. 2019
20.81
Feb 7. 2019
22.09
11 Trading Days
6.16%
Link
LONG
Nov 8. 2019
42.61
Nov 29. 2019
45.79
14 Trading Days
7.47%
Link
LONG
Oct 23. 2020
43.17
Dec 2. 2020
55.01
27 Trading Days
27.43%
Link
LONG
Jun 2. 2021
22.62
Jun 17. 2021
25.86
11 Trading Days
14.34%
Link
Company Information
Stock Symbol
ACAD
Exchange
NasdaqGS
Company URL
http://www.acadia-pharm.com
Company Phone
858-558-2871
CEO
Stephen R. Davis
Headquarters
California
Business Address
3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001070494
About

ACADIA Pharmaceuticals, Inc. engages in the research, development and manufacture of pharmaceutical products. It focuses on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading